Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases.

Abstract

BACKGROUND:

Combination chemotherapy has dramatically improved the prognosis of patients with nondysgerminomatous ovarian germ cell tumors (NDOGCT). However, guidelines are needed for the identification of patients at risk of relapse.

METHODS:

The authors performed a retrospective analysis of women with NDOGCT managed during the period 1970-1994 at the Royal Marsden Hospital and other hospitals of the London Gynaecological Oncology Group.

RESULTS:

Sixty-nine women were included; their median follow-up was 5.7 years (minimum, 12 months). The median age was 21 years (range, 4-44 years), with a histology of immature teratoma (IT) for 17 patients, endodermal sinus tumor (EST) for 20 patients, and mixed tumors for 32 patients. Thirty-five patients (51%) had Stage I disease. Nine patients with Stage I tumors were observed without further therapy (six with IT and three with mixed tumors), and one relapsed. Seven patients received non-platinum-based chemotherapy, and four relapsed. A total of 52 patients were treated with platinum-based chemotherapy, with relapse free and overall survival rates of 87% (95% confidence interval [CI], 73-93%) and 84% (95% CI, 70-91%), respectively. Of these patients, relapse was seen in 0 of 9 IT patients, 1 of 25 patients with mixed tumors, and 6 of 18 EST patients. With alpha-fetoprotein (AFP) > 1000 kU/L, relapse was seen in 6 of 18 patients compared with 1 of 33 relapses with lower AFP levels. In multivariate analysis, including all patients who received chemotherapy, AFP >1000 kU/L (P = 0.001) and non-platinum-based chemotherapy (P = 0.005) were associated with relapse. When only patients given platinum-based treatment were considered, EST histology (P = 0.003) and AFP >1000 kU/L (P = 0.003) were associated with relapse in univariate analysis; however, these factors were linked. No malignant tumor was found at second-look surgery performed on 24 patients. Of 26 women assessable for fertility, 24 subsequently recommenced regular menstrual function, and 11 patients had pregnancies.

CONCLUSIONS:

Platinum-based chemotherapy has been confirmed to be effective in the management of patients with NDOGCT. Relapses were principally seen among patients with AFP >1000 kU/L or pure EST histology. Efforts to improve outcome need to focus on patients with EST, whereas less intensive management strategies may be appropriate for some patients with IT.

• Authors: P L Mitchell, N Al-Nasiri, R A'Hern, C Fisher, A Horwich, C R Pinkerton, J H Shepherd, C Gallagher, M Slevin, P Harper, R Osborne, J Mansi, T Oliver, M E Gore
• Journal: Cancer (Cancer) Vol. 85 Issue 10 Pg. 2232-44 (May 15 1999) ISSN: 0008-543X [Print] United States
• PMID: 10326703 (Publication Type: Journal Article)

Chemical References

• Cisplatin

Topics

• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Child
• Child, Preschool
• Cisplatin (therapeutic use)
• Endodermal Sinus Tumor (drug therapy, pathology)
• Female
• Humans
• Neoplasm Recurrence, Local
• Neoplasms, Germ Cell and Embryonal (drug therapy, pathology)
• Ovarian Neoplasms (drug therapy, pathology)
• Prognosis
• Retrospective Studies
• Teratoma (drug therapy, pathology)
• Treatment Outcome